Floatz logo

Therapeutic Asset Ratings

234 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Tetanus Toxoid
Glioblastoma
Charlotte LemechP2B (56)
Zoladex
Glioblastoma
Nationwide Children's HospitalP2B (56)
Vinorelbine
Glioblastoma
National Cancer Institute (NCI)P2/3B (56)
Catequentinib
glioblastoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolP2CCC (55)
FLUDEOXYGLUCOSE
glioblastoma
Jonsson Comprehensive Cancer CenterP2CCC (55)
FLUTICASONE
Glioblastoma
David PeereboomP2CCC (55)
FULVESTRANT
Glioblastoma
Nationwide Children's HospitalP2CCC (55)
Gliolan
glioblastoma
Universität MünsterP2CCC (55)
Human Cmv Pp65-Lamp Mrna-Pulsed Autologous Dcs
glioblastoma
Annick Desjardins, MDP2CCC (55)
Sargramostim
glioblastoma
Children's Oncology GroupP2CCC (55)
Survaxm
glioblastoma
Children's Oncology GroupP2CCC (55)
Tislelizumab
glioblastoma
Jiangsu Healthy Life Innovation Medical Technology Co., LtdP2CCC (55)
Tofacitinib
glioblastoma
University of Texas Southwestern Medical CenterP3CCC (54)
FDOPA
glioblastoma
Mayo ClinicP2CCC (54)
Montanide Isa 51
glioblastoma
Children's Oncology GroupP2CCC (54)
o6-benzylguanine
glioblastoma
Leland MethenyP2CCC (54)
Retifanlimab
glioblastoma
Academic and Community Cancer Research UnitedP2CCC (54)
Pamiparib
glioblastoma
Nader SanaiP1/2CCC (54)
Pegargiminase
glioblastoma
Sabine Mueller, MD, PhDP2/3CCC (54)
Troriluzole
glioblastoma
Ugonma ChukwuekeP2/3CCC (54)
Vebreltinib
glioblastoma
Huashan HospitalP2/3CCC (54)
g207
glioblastoma
Pediatric Brain Tumor ConsortiumP2CCC (53)
TLX-101-Tx
glioblastoma
Telix Pharmaceuticals (Innovations) Pty LimitedP3CCC (52)
cc-115
glioblastoma
Patrick Wen, MDP2CCC (52)
Lonafarnib
glioblastoma
Duke UniversityP2CCC (52)
Showing 51 to 75 of 234 assets
PreviousPage 3 of 10Next